Monsanto Loses Court Appeal on Patent Case
Monsanto Investing News web page.
Court upholds Enzo patent in antisense
FARMINGDALE, N.Y., Sept 27 (Reuters) - Enzo Biochem Inc.
(AMEX:ENZ - news) said Monday A U.S. Court of Appeals for the
Federal Circuit has rejected an effort by Monsanto Co.'s (NYSE:MTC -
news) Calgene Inc. to invalidate Enzo's patent in genetic antisense
Antisense blocks the process by which a virus or cancer cell takes over a
healthy's cells chemistry to replicate itself. Enzo is developing
antisense technology to fight genetically linked diseases. The decision,
handed down late Friday, ends a long-standing dispute between the two
companies, unless Calgene goes to the Supreme Court. The basic patent
is a broad one that covers both therapeutic and agricultural applications.